Inclusion Criteria:

- Patients must have a history of uveal melanoma and documented metastatic disease

- Patients must have at least one unidimensionally measurable lesion; if this is a
cutaneous lesion it must be at least 10 mm by caliper measure; if it is a visceral or
nodal or soft tissue lesion, it must be clearly measurable > 20 mm with conventional
techniques or > 10 mm with spiral CT scan; bone lesions are not considered measurable

- One prior systemic chemotherapy and any number of immunotherapies or vaccine
therapies are allowed; prior treatment with hepatic arterial chemotherapy infusion or
perfusion or chemoembolization of liver metastasis is allowed; prior treatment with
radiation therapy is allowed but not more than 3000 cGy to fields including
substantial marrow; patients are not required to have had prior therapy

- At least 6 weeks (42 days) since any prior immunotherapy, cytokine, biologic,
vaccine or other therapy unless patients have progressed during therapy; if
progression occurred during therapy, patient must have recovered from any side
effects

- At least 4 weeks (28 days) since prior radiotherapy and prior adjuvant
chemotherapy

- Patients must have ECOG performance status of 0 - 2

- Patients must have a life expectancy of at least 3 months

- Leukocytes > 3,000/mm3

- Absolute neutrophil count ≥ 1,500/mm3

- Hemoglobin ≥ 9.0 g/dL

- Platelets ≥ 100,000/mm3

- AST(SGOT)/ALT(SGPT) ≤ 3 X institutional upper limit of normal (ULN); ≤ 5 X
institutional ULN if liver metastases present

- Total bilirubin < 1.5 X institutional ULN

- Creatinine < 1.5 X institutional ULN OR creatinine clearance ≥ 60 mL/min/1.73 m2 for
patients with creatinine levels above institutional normal

- Fasting serum glucose < 120 mg/dL or < institutional ULN

- Patients must have no angina at rest

- The effects of IMC-A12 on the developing human fetus at the recommended therapeutic
dose are unknown; for this reason and because monoclonal antibodies could be
teratogenic, women of child-bearing potential and men must agree to use adequate
contraception (hormonal or barrier method of birth control; abstinence) prior to
study entry and for the duration of study participation and for 3 months after the
last dose of IMC-A12; should a woman become pregnant or suspect she is pregnant while
participating in this study, she should inform her treating physician immediately

- Both men and women and members of all races and ethnic groups are eligible for this
trial

- Patients must have the ability to understand and the willingness to sign a written
informed consent form indicating that they are aware of the investigational nature of
this study and in keeping with the policies of the institution

Exclusion Criteria:

- Patients whose site of primary melanoma is not uveal

- Patients who have a current history of neoplasm other than the entry diagnosis except
for curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix or
other cancers treated for cure and with a disease-free survival longer than 5 years

- Patients with symptomatic central nervous system metastasis including those with CNS
metastasis who require oral steroids for cerebral edema or have progression on CT/MRI

- Patients who are pregnant or nursing and patients who are not practicing an
acceptable method of birth control; patients may not breast-feed while on this study;
pregnant women are excluded from this study because IMC-A12 is a monoclonal antibody
with the potential for teratogenic or abortifacient effects; because there is an
unknown but potential risk for adverse events in nursing infants secondary to
treatment of the mother with IMC-A12, breastfeeding women are excluded

- Patients with current active infections requiring anti-infectious treatment (e.g.,
antibiotics, antivirals, or antifungals)

- Patients with poorly controlled diabetes mellitus; patients with a history of
diabetes mellitus are allowed to participate, provided that their blood glucose is
within normal range (fasting < 120 mg/dL or below institutional ULN) and that they
are on a stable dietary or therapeutic regimen for this condition

- Patients with unstable or serious concurrent medical conditions are excluded;
examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent
(within 3 months) myocardial infarction, uncontrolled major seizure disorder, spinal
cord compression, superior vena cava syndrome, or any psychiatric disorder that
prohibits obtaining informed consent

- Patients with one or more of the following as the only manifestations of disease are
ineligible: leptomeningeal disease, ascites, pleural/pericardial effusions,
carcinomatous lymphangitis

- Patients with Gilbert's Syndrome

- Patients must not have had major surgery within the past 14 days

- Patients must not receive any concurrent chemotherapy or immunotherapy while on
study; only palliative radiotherapy is permitted to symptomatic lesions in which
event the irradiated lesions may not be considered target or non-target lesions for
response; palliative radiation immediately before or during the study is acceptable
provided there is evaluable disease that has been radiated; palliative radiation is
acceptable provided that the irradiated lesions are not used to determine response
assessment

- HIV-positive patients with an absolute CD4 count < 300 K/uL

- Patients may not be receiving any other investigational agents

- Patients with a history of treatment with other agents targeting the insulin-like
growth factor pathway

- Patients with a history of allergic reactions attributed to compounds of similar
chemical or biologic composition to IMC-A12